Alternative Splicing in Cancer and Immune Cells.

Fiche publication

Date publication

mars 2022

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOIDOT Romain , Dr VEGRAN Frédérique

Tous les auteurs :
Bernard A, Boidot R, Végran F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35406498

Résumé

Splicing is a phenomenon enabling the excision of introns from pre-mRNA to give rise to mature mRNA. All the 20,000 genes of the human genome are concerned by this mechanism. Nevertheless, it is estimated that the proteome is composed of more than 100,000 proteins. How to go from 20,000 genes to more than 100,000 proteins? Alternative splicing (AS) is in charge of this diversity of proteins. AS which is found in most of the cells of an organism, participates in normal cells and in particular in immune cells, in the regulation of cellular behavior. In cancer, AS is highly dysregulated and involved in almost all of the hallmarks that characterize tumor cells. In view of the close link that exists between tumors and the immune system, we present in this review the literature relating to alternative splicing and immunotherapy. We also provide a global but not exhaustive view of AS in the immune system and tumor cells linked to the events that can lead to AS dysregulation in tumors.